| %fPSA | Percent free PSA |
| ADT | Androgen deprivation therapy |
| AI | Artificial intelligence |
| APC | Adenomatous polyposis coli |
| AR | Androgen receptor |
| AS | Active surveillance |
| ASCO | American Society of Clinical Oncology |
| ATM | Ataxia-telangiectasia mutated |
| AUA | American Urological Association |
| BCR | Biochemical relapse |
| BRCA | Breast cancer gene |
| CAPRA | Cancer of the Prostate Risk Assessment |
| CCP | Cell-cycle progression |
| CCR | Clinical cell-cycle risk |
| cfDNA | Cell-free DNA |
| CHEK2 | Checkpoint kinase 2 |
| cPSA | Complexed PSA |
| csPC | Clinically significant prostate cancer |
| CSS | Cancer-specific survival |
| CTCs | Circulating tumor cells |
| ctDNA | Circulating tumor DNA |
| DAPK | Death-associated protein kinase 1 |
| DLX1 | Distal-less homeobox 1 |
| DRE | Digital rectal examination |
| EAU | European Association of Urology |
| EBRT | External beam RT |
| ERSPC | European Randomised Study for Screening of Prostate Cancer |
| FDA | Food and Drug Administration |
| FOXA1 | Forkhead box protein A1 |
| fPSA | Free PSA |
| GADD45 | Growth arrest and DNA-damage-inducible α |
| GPS | Genomic Prostate Score |
| GS | Gleason score |
| GSTP1 | Glutathione-S-transferase P1 / Glutathione-S-transferase π |
| HER2 | Human epidermal growth factor receptor 2 |
| HOXB13 | Omeobox B13 |
| HRR | Homologous recombination repair |
| iPARP | Poly-ADP ribose polymerase RASSF inhibitor |
| ISUP | International Society of Urological Pathology |
| mCRPC | Metastatic castration-resistant prostate cancer |
| MFS | Metastasis-free survival |
| MiPS | Mi Prostate Score |
| MLH1 | MutL protein homolog 1 |
| MMR | Mismatch repair |
| MpMRI | Multiparametric magnetic resonance imaging |
| NCCN | National Comprehensive Cancer Network |
| NGI | Next-generation imaging |
| NICE | National Institute for Health and Care Excellence |
| NPV | Negative predictive value |
| OS | Overall survival |
| PALB2 | Partner and localizer of BRCA2 |
| PC | Prostate cancer |
| PCA 3 | Prostate cancer antigen 3 |
| PHI | Prostate Health Index |
| PI-RADS | Prostate Imaging Reporting & Data System |
| PMS2 | Postmeiotic segregation increased 2 |
| PSA | Prostate-specific antigen |
| PSA-D | PSA density |
| PSMA-PET/CT | Prostate-specific membrane antigen–positron emission tomography/computed tomography |
| PTEN | Phosphatase and tensin homolog |
| QoL | Quality of life |
| RASSF1 | Ras association domain family member 1 / Ras association domain-containing protein 1 |
| RB1 | Retinoblastoma transcriptional corepressor |
| RP | Radical prostatectomy |
| RT | Radiotherapy |
| RTOG | Radiation Therapy Oncology Group |
| RUNX3 | Runt-related transcription factor 3 |
| SEER | Surveillance, Epidemiology, and End Results |
| SNPs | Single-nucleotide polymorphisms |
| SNVs | Single-nucleotide variants |
| SPOP | Speckle-type POZ protein |
| TGFβ | Transforming growth factor β |
| TME | Tumor microenvironment |
| TMPRSS2:ERG | The fusion of the transmembrane protease serine 2 gene with the erythroblast transformation-specific-related gene |
| TNFRSF10c | Tumor necrosis factor receptor superfamily member 10c |
| tPSA | Total PSA |
| US | United States |